← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Emmune, Inc
Juno Beach, FL
$20,436,743
Total funding
11
Grants
Funding over time
peak $3.3M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,436,743 · 11
By mechanism
R44$18,695,515 · 7
R56$917,294 · 1
R43$823,934 · 3
Investigators at Emmune, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Engineering AAV capsids for enhanced transduction of skeletal muscle$1,012,172
R44 · FY2023 · TR
Engineering AAV capsids for enhanced transduction of skeletal muscle$1,012,172
R44 · FY2022 · TR
Glycoengineering eCD4-Ig$1,000,000
R44 · FY2023 · AI
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites$1,000,000
R44 · FY2023 · AI
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites$1,000,000
R44 · FY2025 · AI
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites$1,000,000
R44 · FY2024 · AI
Process development for manufacturing eCD4-Ig$999,997
R44 · FY2025 · AI
Development of AAV vectors for long-term expression of eCD4-Ig$999,959
R44 · FY2018 · AI
Development of AAV vectors for long-term expression of eCD4-Ig$999,675
R44 · FY2019 · AI
Development of AAV vectors for long-term expression of eCD4-Ig$999,443
R44 · FY2020 · AI
WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?$998,663
R44 · FY2018 · AI
Glycoengineering eCD4-Ig$974,663
R44 · FY2022 · AI
Glycoengineering eCD4-Ig$974,661
R44 · FY2024 · AI
WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?$937,245
R44 · FY2017 · AI
Non-viral gene therapy with eCD4-Ig$917,294
R56 · FY2025 · AI
Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig$907,386
R44 · FY2022 · AI
Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig$886,103
R44 · FY2020 · AI
Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig$870,946
R44 · FY2021 · AI
Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig$300,000
R44 · FY2019 · AI
Glycoengineering eCD4-Ig$300,000
R44 · FY2021 · AI